Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Steven Leeds

Surgery Dallas, TX Medical Doctor

NPI 1467689604 CMS profile 248530

3410 Worth St. Suite 235, Dallas, TX 75246

Open in the dashboard

General payments

$193,256

352 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$24,113 paid to institutions, not to them · program years 2021–2023

Through program year 2025, Steven Leeds of Dallas, TX is reported in the CMS Open Payments database as having received $193,256 across 352 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $24,113 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 98th percentile of Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $900 16
2024 General $3,450 16
2023 General $10,400 25
2022 General $38,722 78
2021 General $24,471 42
2020 General $23,455 24
2019 General $91,859 151

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Steven Leeds
  • Surgery median
  • Middle half of Surgery
  • National median

In program year 2025, general payments to Steven Leeds were reported at $900. Among 17,702 Surgery profiles paid that year, the median was $280 and the middle half received between $91 and $1,259.

Show as a table
Year Steven Leeds Surgery median Middle half National median
2019 $91,859 $253 $82–$1,521 $163
2020 $23,455 $131 $40–$706 $114
2021 $24,471 $168 $50–$904 $132
2022 $38,722 $224 $76–$1,218 $149
2023 $10,400 $253 $82–$1,255 $160
2024 $3,450 $279 $90–$1,381 $164
2025 $900 $280 $91–$1,259 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Medical Device Business Services, Inc. $82,286 134 payments
  2. Ethicon US, LLC $74,163 75 payments
  3. Boston Scientific Corporation $25,736 45 payments
  4. Intuitive Surgical, Inc. $6,096 20 payments
  5. Allergan Inc. $1,080 20 payments
  6. Ethicon Inc. $1,040 1 payment
  7. Davol Inc. $658 9 payments
  8. Enterra Medical, Inc. $652 5 payments
  9. Integra LifeSciences Corporation $259 9 payments
  10. AbbVie, Inc. $195 6 payments
  11. Other $1,091 28 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $148,887 54 payments
  2. Travel and Lodging $19,472 73 payments
  3. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $13,888 7 payments
  4. Food and Beverage $11,010 218 payments
Products named General payments · program years 2019–2025
  1. LINX Reflux Management System Endo-Mechanical $99,379 128 payments
  2. GENERAL HEMOSTASIS $5,294 4 payments
  3. RESOLUTION CLIP $5,146 7 payments
  4. Da Vinci Surgical System $3,096 18 payments
  5. DA VINCI SP $3,000 2 payments
  6. General - Therapies $2,307 4 payments
  7. PHYSIOMESH $1,600 1 payment
  8. SECURESTRAP $1,600 1 payment
  9. GENERAL THERAPIES $925 2 payments
  10. LINX Reflux Management System Endo-Mechanical $866 12 payments
  11. Other $8,285 147 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 2 drugs

Part D claims

52

Median for General Surgery: 59

Drug cost

$369

Median for General Surgery: $393

Branded share of claims

69.2%

Median for General Surgery: 28.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Pantoprazole Sodium Generic 16 $249
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 36 $119

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 15,891 Part D prescribers listed as General Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 55 billing codes

Paid by Medicare

$95,496

Medicare's payments for the services billed

Medicare patients

144

Average age 72

Services billed

412

100 women, 44 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 56%
Depression 36%
Ischemic heart disease 35%
Diabetes 28%
COPD 28%
Chronic kidney disease 25%
Heart failure 19%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

352 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Surgery in Texas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record